FDA looks to further ease biosimilar approvals
A March 9 draft guidance from the FDA proposes an allowance for biosimilar sponsors to use clinical data from outside the U.S. to seek the agency’s approval, which would reduce the requirement of at least one study in the approval process. Current FDA guidance requires drugmakers to conduct at least one pharmacokinetic study that directly […]
Continue Reading